Transaction in Own Shares

PureTech Health PLC
23 October 2023
 

23 October 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:             

20 October 2023



Number of ordinary shares purchased:

30,962



Highest price paid per share:

168.80p



Lowest price paid per share:

162.60p



Volume weighted average price paid per share:

166.20p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 15,673,503 ordinary shares in treasury and has 273,794,656 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,794,656 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

20/10/2023

08:07:43

130

162.6

AQXE

00374738779TRLO0.1.1

20/10/2023

10:15:14

168

164.2

BATE

00374767645TRLO0.1.1

20/10/2023

10:17:50

33

164.2

AQXE

00374768553TRLO0.1.1

20/10/2023

10:21:29

310

164.2

XLON

00374769350TRLO0.1.1

20/10/2023

10:21:29

98

164.2

XLON

00374769351TRLO0.1.1

20/10/2023

10:21:35

522

164.2

XLON

00374769413TRLO0.1.1

20/10/2023

10:21:35

598

164.2

XLON

00374769414TRLO0.1.1

20/10/2023

10:21:43

56

164.2

AQXE

00374769491TRLO0.1.1

20/10/2023

10:21:43

142

164.2

BATE

00374769492TRLO0.1.1

20/10/2023

10:21:43

310

164.2

CHIX

00374769493TRLO0.1.1

20/10/2023

10:21:43

214

164.2

BATE

00374769494TRLO0.1.1

20/10/2023

10:21:43

105

164.2

AQXE

00374769495TRLO0.1.1

20/10/2023

10:21:51

280

164.6

XLON

00374769518TRLO0.1.1

20/10/2023

10:21:51

73

164.6

XLON

00374769520TRLO0.1.1

20/10/2023

10:21:51

62

164.6

XLON

00374769519TRLO0.1.1

20/10/2023

10:30:15

61

164

XLON

00374771518TRLO0.1.1

20/10/2023

10:30:36

194

164

AQXE

00374771575TRLO0.1.1

20/10/2023

10:30:36

806

164

XLON

00374771576TRLO0.1.1

20/10/2023

10:31:18

373

164

XLON

00374771750TRLO0.1.1

20/10/2023

10:31:19

406

164

XLON

00374771754TRLO0.1.1

20/10/2023

10:31:19

151

164

XLON

00374771753TRLO0.1.1

20/10/2023

10:53:59

502

166.4

XLON

00374776322TRLO0.1.1

20/10/2023

10:53:59

98

166.6

XLON

00374776323TRLO0.1.1

20/10/2023

10:57:00

307

166.6

XLON

00374777292TRLO0.1.1

20/10/2023

11:30:38

43

168.2

XLON

00374784296TRLO0.1.1

20/10/2023

11:30:38

85

168.2

XLON

00374784297TRLO0.1.1

20/10/2023

11:30:38

12

168.2

XLON

00374784298TRLO0.1.1

20/10/2023

11:31:11

311

168.2

XLON

00374784409TRLO0.1.1

20/10/2023

11:31:21

295

168.4

XLON

00374784437TRLO0.1.1

20/10/2023

11:31:21

61

168.4

XLON

00374784438TRLO0.1.1

20/10/2023

11:31:21

200

168.4

XLON

00374784439TRLO0.1.1

20/10/2023

11:39:49

310

168.8

CHIX

00374786564TRLO0.1.1

20/10/2023

11:39:56

930

167.8

XLON

00374786580TRLO0.1.1

20/10/2023

11:43:25

96

167.2

TRQX

00374787822TRLO0.1.1

20/10/2023

11:43:25

81

167.2

TRQX

00374787821TRLO0.1.1

20/10/2023

11:43:25

15

167.2

TRQX

00374787823TRLO0.1.1

20/10/2023

11:43:25

95

167.2

CHIX

00374787825TRLO0.1.1

20/10/2023

11:43:25

215

167.2

CHIX

00374787824TRLO0.1.1

20/10/2023

11:43:25

930

167.4

XLON

00374787826TRLO0.1.1

20/10/2023

11:43:25

100

167.2

CHIX

00374787828TRLO0.1.1

20/10/2023

11:43:25

210

167.2

CHIX

00374787827TRLO0.1.1

20/10/2023

11:43:25

143

166.8

BATE

00374787829TRLO0.1.1

20/10/2023

11:43:25

3

166.8

BATE

00374787831TRLO0.1.1

20/10/2023

11:43:25

4

166.8

BATE

00374787830TRLO0.1.1

20/10/2023

11:43:25

54

166.8

BATE

00374787832TRLO0.1.1

20/10/2023

12:19:36

68

168

XLON

00374794666TRLO0.1.1

20/10/2023

12:19:36

69

168

XLON

00374794667TRLO0.1.1

20/10/2023

12:24:31

194

168.2

AQXE

00374795760TRLO0.1.1

20/10/2023

12:31:46

175

167.2

BATE

00374797020TRLO0.1.1

20/10/2023

12:31:46

496

168

XLON

00374797021TRLO0.1.1

20/10/2023

12:31:46

7

167.2

TRQX

00374797022TRLO0.1.1

20/10/2023

12:31:46

310

167.2

CHIX

00374797023TRLO0.1.1

20/10/2023

12:31:46

96

167.2

TRQX

00374797025TRLO0.1.1

20/10/2023

12:31:46

190

167.2

CHIX

00374797024TRLO0.1.1

20/10/2023

12:31:46

89

167.2

TRQX

00374797026TRLO0.1.1

20/10/2023

12:31:46

54

167.2

BATE

00374797028TRLO0.1.1

20/10/2023

12:31:46

81

167.2

BATE

00374797027TRLO0.1.1

20/10/2023

12:31:46

310

167.2

BATE

00374797029TRLO0.1.1

20/10/2023

12:31:46

103

168

XLON

00374797030TRLO0.1.1

20/10/2023

12:31:46

194

167.4

AQXE

00374797031TRLO0.1.1

20/10/2023

12:31:46

403

168

XLON

00374797032TRLO0.1.1

20/10/2023

12:31:46

19

167.4

XLON

00374797033TRLO0.1.1

20/10/2023

12:31:46

3800

167.4

XLON

00374797034TRLO0.1.1

20/10/2023

12:38:09

238

166.4

XLON

00374798319TRLO0.1.1

20/10/2023

12:53:10

14

165.2

XLON

00374801096TRLO0.1.1

20/10/2023

12:53:10

74

165.2

XLON

00374801095TRLO0.1.1

20/10/2023

13:18:19

350

165.8

XLON

00374805821TRLO0.1.1

20/10/2023

13:18:19

45

165.8

XLON

00374805822TRLO0.1.1

20/10/2023

13:18:19

15

165.8

XLON

00374805823TRLO0.1.1

20/10/2023

13:18:19

91

165.8

XLON

00374805824TRLO0.1.1

20/10/2023

13:47:38

287

165.2

BATE

00374811970TRLO0.1.1

20/10/2023

13:47:38

96

165.2

TRQX

00374811971TRLO0.1.1

20/10/2023

13:47:38

195

165.2

BATE

00374811972TRLO0.1.1

20/10/2023

13:47:38

800

165.2

XLON

00374811973TRLO0.1.1

20/10/2023

13:47:38

440

165.2

XLON

00374811974TRLO0.1.1

20/10/2023

13:47:38

194

165.2

AQXE

00374811975TRLO0.1.1

20/10/2023

14:30:01

194

166.6

AQXE

00374823479TRLO0.1.1

20/10/2023

14:30:05

430

166.4

CHIX

00374823671TRLO0.1.1

20/10/2023

14:32:55

310

166.2

CHIX

00374825293TRLO0.1.1

20/10/2023

14:34:26

324

165.8

XLON

00374825853TRLO0.1.1

20/10/2023

15:04:17

310

166

BATE

00374836483TRLO0.1.1

20/10/2023

15:04:17

310

166

BATE

00374836484TRLO0.1.1

20/10/2023

15:04:17

1240

166

XLON

00374836485TRLO0.1.1

20/10/2023

15:04:23

110

166

AQXE

00374836500TRLO0.1.1

20/10/2023

15:06:20

84

166

AQXE

00374837293TRLO0.1.1

20/10/2023

15:06:20

31

165.8

CHIX

00374837295TRLO0.1.1

20/10/2023

15:06:20

126

166

AQXE

00374837294TRLO0.1.1

20/10/2023

15:06:20

13

165.8

CHIX

00374837297TRLO0.1.1

20/10/2023

15:06:20

96

165.8

TRQX

00374837296TRLO0.1.1

20/10/2023

15:09:05

298

165.8

CHIX

00374838392TRLO0.1.1

20/10/2023

15:09:05

266

165.8

CHIX

00374838391TRLO0.1.1

20/10/2023

15:09:05

1240

165.6

XLON

00374838393TRLO0.1.1

20/10/2023

15:26:28

611

165.8

XLON

00374845340TRLO0.1.1

20/10/2023

15:32:01

23

165.6

XLON

00374847907TRLO0.1.1

20/10/2023

15:32:01

310

165.6

XLON

00374847906TRLO0.1.1

20/10/2023

15:39:31

96

166

TRQX

00374851365TRLO0.1.1

20/10/2023

15:39:42

3

166

BATE

00374851413TRLO0.1.1

20/10/2023

16:02:11

242

166

CHIX

00374871099TRLO0.1.1

20/10/2023

16:07:36

516

166.2

XLON

00374873407TRLO0.1.1

20/10/2023

16:07:36

279

166.2

XLON

00374873408TRLO0.1.1

20/10/2023

16:07:36

50

166.2

XLON

00374873409TRLO0.1.1

20/10/2023

16:07:36

275

166.2

CHIX

00374873412TRLO0.1.1

20/10/2023

16:07:36

194

166.2

AQXE

00374873411TRLO0.1.1

20/10/2023

16:07:36

160

166.2

XLON

00374873414TRLO0.1.1

20/10/2023

16:07:36

35

166.2

CHIX

00374873413TRLO0.1.1

20/10/2023

16:07:36

545

166.2

XLON

00374873415TRLO0.1.1

20/10/2023

16:10:40

82

166

BATE

00374874880TRLO0.1.1

20/10/2023

16:10:40

50

166

BATE

00374874881TRLO0.1.1

20/10/2023

16:10:40

15

166

BATE

00374874884TRLO0.1.1

20/10/2023

16:10:40

1550

166

XLON

00374874882TRLO0.1.1

20/10/2023

16:10:40

163

166

BATE

00374874883TRLO0.1.1

20/10/2023

16:21:46

390

166.2

CHIX

00374881460TRLO0.1.1

20/10/2023

16:22:44

192

166.2

CHIX

00374882090TRLO0.1.1

20/10/2023

16:23:47

110

166

AQXE

00374882613TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings